All In Biotech

Drug Trial Radar · NCT04368728

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 46,969 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

46,969

Actual

Start

Apr 29, 2020

Primary completion

Feb 10, 2023

Study completion Feb 10, 2023

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Apr 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part. The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate: * As a 2-dose (separated by 21 days) schedule; * At various different dose levels in Phase 1; * As a booster; * In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age \[stratified as 12-15, 16-55 or \>55 years of age\]). The candidate selected for efficacy evaluation in Phase 2/3 is BNT162b2 at a dose of 30 µg. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study. In order to describe the boostability of BNT162, and potential heterologous protection against emerging SARS-CoV-2 VOCs, an additional dose of BNT162b2 at 30 µg will be given to Phase 1 participants approximately 6 to 12 months after their second dose of BNT162b1 or BNT162b2. This will provide an early assessment of the safety of a third dose of BNT162, as well as its immunogenicity. The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a third and potentially a fourth dose of prototype BNT162b2VOC at 30 µg (BNT162b2s01, based upon the South African variant and hereafter referred to as BNT162b2SA). A further subset of Phase 3 participants will receive a third, lower, dose of BNT162b2 at 5 or 10 µg. To further describe potential homologous and heterologous protection against emerging SARS-CoV-2 VOCs, a new cohort of participants will be enrolled who are COVID-19 vaccine-naïve (ie, BNT162b2-naïve) and have not experienced COVID-19. They will receive BNT162b2SA given as a 2-dose series, separated by 21 days. To reflect current and anticipated recommendations for COVID 19 vaccine boosters, participants in C4591001 who meet specified recommendations and have not already received one, will be offered a third dose of BNT162b2 after their second dose of BNT162.

Conditions

  • SARS-CoV-2 Infection
  • COVID-19

Interventions

  • BNT162b1Biological

    Intramuscular injection

  • BNT162b2Biological

    Intramuscular injection

  • PlaceboOther

    Intramuscular injection

  • BNT162b2SABiological

    Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1Time frame: Within 7 days after Dose 1
  2. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 1Time frame: Within 7 days after Dose 2
  3. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 1Time frame: Within 7 days after Dose 1
  4. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 1Time frame: Within 7 days after Dose 2
  5. Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 1Time frame: From Dose 1 to 1 Month After Dose 2
  6. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 1Time frame: From Dose 1 to 6 Months After Dose 2
  7. Percentage of Participants With Abnormalities in Hematology Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
  8. Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
  9. Percentage of Participants With Abnormalities in Hematology Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
  10. Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
  11. Percentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
  12. Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
  13. Percentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
  14. Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
  15. Percentage of Participants With Grade Shift in Hematology Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
  16. Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
  17. Percentage of Participants With Grade Shift in Hematology Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
  18. Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
  19. Percentage of Participants With Grade Shift in Chemistry Parameters 1 Day After Dose 1: Phase 1Time frame: 1 Day After Dose 1
  20. Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 1: Phase 1Time frame: 7 Days After Dose 1
  21. Percentage of Participants With Grade Shift in Chemistry Parameters Before Dose 2: Phase 1Time frame: Before Dose 2
  22. Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 2: Phase 1Time frame: 7 Days After Dose 2
  23. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2/3Time frame: Within 7 Days after Dose 1
  24. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2/3Time frame: Within 7 Days after Dose 2
  25. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2/3Time frame: Within 7 Days after Dose 1
  26. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2/3Time frame: Within 7 Days after Dose 2
  27. Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/3Time frame: From Dose 1 to 1 Month After Dose 2
  28. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/3Time frame: From Dose 1 to 6 Months After Dose 2
  29. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2Time frame: Within 7 Days after Dose 1
  30. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2Time frame: Within 7 Days after Dose 2
  31. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2Time frame: Within 7 Days after Dose 1
  32. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2Time frame: Within 7 Days After Dose 2
  33. Percentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2Time frame: From Dose 1 to 7 Days After Dose 2
  34. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2Time frame: From Dose 1 to 7 Days After Dose 2
  35. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: Within 7 Days After Booster Dose
  36. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: Within 7 Days After Booster Dose
  37. Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: From First Booster Dose to 1 Month After Booster Dose
  38. Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster DoseTime frame: From First Booster Dose to 6 Months After Booster Dose
  39. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days After Booster Dose 1
  40. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days after Booster Dose 2
  41. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days After Booster Dose 1
  42. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: Within 7 Days After Booster Dose 2
  43. Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: From First Booster Dose to 1 Month After Second Booster Dose
  44. Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SATime frame: From First Booster Dose to 5 Months After Second Booster Dose
  45. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 1
  46. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 2
  47. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 1
  48. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SATime frame: Within 7 Days After Dose 2
  49. Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SATime frame: From Dose 1 Through 1 Month After Dose 2
  50. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SATime frame: From Dose 1 to 6 Months After Dose 2
  51. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: Within 7 days After Booster Dose
  52. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: Within 7 days After Booster Dose
  53. Percentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: From Booster Dose to 1 Months After Booster Dose
  54. Percentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)Time frame: From Booster Dose to 6 Months after Booster Dose
  55. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.247, Placebo - 6.003)
  56. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.214, Placebo - 2.222)
  57. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.509, Placebo - 6.274)
  58. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.332, Placebo - 2.345)
  59. GMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 3Time frame: 1 Month After Dose 2
  60. Percentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3Time frame: 1 Month After Dose 2
  61. GMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
  62. Percentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
  63. GMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
  64. Percentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

Locations

175 sites in 6 countries. Site status is shown where the registry gives one.

  • North Alabama Research Center, LLC

    Athens, Alabama

  • Birmingham Clinical Research Unit

    Birmingham, Alabama

  • Medical Affiliated Research Center

    Huntsville, Alabama

  • Optimal Research, LLC

    Huntsville, Alabama

  • Alliance for Multispecialty Research, LLC

    Mobile, Alabama

  • Chinle Comprehensive Health Care Facility

    Chinle, Arizona

  • Johns Hopkins Center for American Indian Health

    Chinle, Arizona

  • HOPE Research Institute

    Phoenix, Arizona

  • The Pain Center of Arizona

    Phoenix, Arizona

  • HOPE Research Institute

    Phoenix, Arizona

  • Alliance for Multispecialty Research, LLC

    Tempe, Arizona

  • Johns Hopkins Center for American Indian Health

    Whiteriver, Arizona

  • Whiteriver Indian Hospital - Garrett Building

    Whiteriver, Arizona

  • Whiteriver Indian Hospital

    Whiteriver, Arizona

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • Collaborative Neuroscience Research, LLC. - Investigator Site File Location

    Garden Grove, California

  • Collaborative Neuroscience Research, LLC

    Long Beach, California

  • Long Beach Clinical Trials Services Inc.

    Long Beach, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • National Research Institute

    Los Angeles, California

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California

  • Paradigm Clinical Research Center

    Redding, California

  • Kaiser Permanente Sacramento

    Sacramento, California

  • Clinical and Translational Science Center (CTSC) Clinical Research Center (CCRC)

    Sacramento, California

  • University of California Davis Health

    Sacramento, California

  • California Research Foundation

    San Diego, California

  • Kaiser Permanente Santa Clara

    Santa Clara, California

  • Bayview Research Group

    Valley Village, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Lynn Institute of Denver

    Aurora, Colorado

  • Clinical Research Consulting, LLC

    Milford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Yale Center for Clinical Investigations (CSRU)

    New Haven, Connecticut

  • Alliance for Multispecialty Research

    Coral Gables, Florida

  • DeLand Clinical Research Unit

    DeLand, Florida

  • Fleming Island Center for Clinical Research

    Fleming Island, Florida

  • Indago Research & Health Center, Inc

    Hialeah, Florida

  • Research Centers of America

    Hollywood, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.